Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	**Ms_JPRI_61898**
Title of the Manuscript:	**An Immunological Outlook on SARS Coronavirus and Its Current Clinical Status**
Type of the Article	**Review Article**

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty'**, provided the manuscript is scientifically robust and technically sound.
To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(http://www.sciencedomain.org/journal/10/editorial-policy)

SDI Review Form 1.6

PART 1: **Review Comments**

	Reviewer's comment	**Author's comment** *(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)*
Compulsory REVISION comments		
Minor REVISION comments	The main observations are summarized. In view of its contents, the present manuscript can be accepted for publication after minor revision with the following comments: 1. Please, add an acronym section and define all the abbreviations and terminologies. 2. In the introduction section the contributions of the study it is not clear. All the key contributions of the study should be explained in a very precise manner. 3. The figures must be re-plotted with higher resolution as well as higher font size as in the current format will appear blurry in the final version of publication upon the acceptance of the paper. In addition, more descriptive information should be provided about them. 4. The main contributions of this study should be clarified considering the existing studies in the relevant literature. 5. In the conclusion section, All the findings of the work should be presented in the bullet format 6. More achievements along with more future recommendations should be provided in the conclusion.	1. The find the acronym section added before the reference section in the manuscript where all the abbreviations and terminologies were indexed. 2. All the key contributions of the study were precisely explained in a very precise manner in the introduction part. 3. The figures were re-plotted with high resolutions and the figures were described in the text of the manuscript. Please find all the figures in .jpg file format in the attachments of the mail. 4. The contributions till date for covid-19 pandemic were explained and clarified with relevant literatures. Recent developments till October 9th 2020 for covid-19 across the globe were explained. The evolution of covid-19 vaccine development statistics across the globe were discussed with figures. 5. In the conclusion part, the future research area for covid-19 were presented in the bullet form. 6. New achievements like 'Covaxin', 'CRISPR based Feluda', 'Floki, a Springer Spaniel which is being trained to detect signs of coronavirus infection in human sweat', 'Union Health Minister Harsh Vardhan releases the AYUSH ministry's Covid treatment protocol on 6 October 2020' etc. were explained in the manuscript text. 7. Future recommendations after the whole studies were presented in the conclusion part. As the authors wanted to explain the recent clinical pipeline for covid19 vaccine development, the vaccine candidates are under clinical trial. So, till the vaccine will ready, we should take the precautionary measures as we know from the proverb, "Prevention is better than cure." 8. A little modification in the article title ' **An Immunological Outlook on SARS Coronavirus (SARS-CoV-2) and Its Current Clinical Status'** 9. All the authors wish to thank you for your valuable comments.
Optional/General comments		

PART 2:

	Reviewer's comment	**Author's comment** *(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)*
Are there ethical issues in this manuscript?	*(If yes, Kindly please write down the ethical issues here in details)*	